## INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

04734.0004-00000 Atty. Docket No. Appln. No. 10/073,307 **Applicant** Hartmut STROBEL et al. Filing Date **F** February 13, 2002 Group: 1624 1014 JUN 1 3 2002 **U.S. PATENT DOCUMENTS** Examiner Initial\* Document Filing Date If Appropriate **Issue Date** Name **Class** Sub Number Class 4,192,888 3/11/80 424 4/10/78 Bondinell et al. 321

		FOREIGN PATI	ENT DOCUMENT	s		
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
OR_	WO 96/01817	1/25/96	PCT	,		
ØR.	WO 99/47153	9/23/99	PCT		<del></del> >	
ØL	WO 00/03746	1/27/00	PCT			
(VOR	WO 00/51970	9/8/00	PCT			
W.	0,253,357	1/20/88	Europe			No
(De	0,420,064	4/3/91	Europe	-		Yes
<del></del>						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
<b>&amp;</b>	Cannon et al., Centrally Acting Emetics. 6. Derivatives of β-Naphthylamine and 2-Indanamine, Journal of Medicinal Chemistry, 1972, Vol. 15, No. 4, 348-350				
ØR.	Cannon et al., Rigid Amino Acids Related to $\alpha$ -Methyldopa, Journal of Medicinal Chemistry, 1974, Vol. 17, No. 5, 565-568				
WK.	Cannon et al., Conformationally Restricted Congeners of Dopamine Derived from 2-Aminoindan, Journal of Medicinal Chemistry, 1982, 25, 1442-1446				
OR.	Colette, et al., Étude Des Nitrosochlorures De L'Indéne Et De Ses Homologues, Ann. Chim. 1976, p. 269-276				

Examiner	Ongel land	Date Considered 3/19/03.						
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce						



						Pro
Atty. Docket No.	04734.0004-00000		Appln. No. 10/	073,307		JUNIO
Applicant JUN 1 8 2000						
Filing Date	February 13, 2002		Group: -161	4 1624	TF	CH OCT
JUN 1	3 2002					CH CENTER 1600/29
E	36.	U.S. PATENT	DOCUMENTS			, , ,
Examiner d 184	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
			-,,			
		FOREIGN PATE	NT DOCUMENTS			
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
						^
-	OTHER DOCUMENT	TC (Including Au	thor Title Date D	lastinant D	)	
		***************************************				
NPB .	Copinga et al., 2-Amido-8-methoxytetralins: A Series of Nonindolic Melatonin-like Agents, J. Med. Chem. 1993, 36, 2891-2898					
(DB)	Peter A. Crooks, A new synthesis of 2-aminoindanes, Chemistry and Industry, 15 June 1974, 495					
ØS.	Devocelle et al., Alternative synthesis of the chiral atypical β-adrenergic phenylethanolaminotetraline agonist SR58611A using enantioselective hydrogenation, Tetrahedron Letters 40 (1999) 4551-4554					
Qy_	Endres et al., Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. USA, Vol. 95, 8880-8885, July 1998					
OB.	Hillver et al., (S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralin: A Putative 5-HT <sub>1A</sub> -Receptor Antagonist, J. Med. Chem., 1990, 33, 1541-1544					
OPR	Itoh et al., The Syntheses and β-Adrenoceptor Activities of N-Substituted 2-Amino-5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthalenols, Chem. Pharm. Bull. 25(11) 2917-2928 (1977)					
ÓL.	Li et al., Activation of Protein Kinase Cα and/or ε Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Molecular Pharmacology, 53:630-637 (1998)					
OL.	Malapel-Andrieu et al., Palladium-Catalyzed Reactions of Indolic Triflate with Allylic Alcohols, Tetrahedron Letters 39 (1998) 39-42					
Examiner	10 V/18	· ·	Date Considered	- اورا -	.9	
	al if reference conside	red whether or no	<del></del>	3 19 0		200: draw line

through citation if not in conformance and not considered. Include copy of this form with next

Patent and Trademark Office - U.S. Department of Commerce

Form PTO 1449

communication to applicant.

## **INFORMATION DISCLOSURE CITATION**

Atty. Docket No.	04734.0004-00000		Appln. No. 10/	073,307	RECE		
Atty. Docket No. 04734.0004-00000  Applicant Hartmut STROBEL et al.  Filing Date O Fet Pary 13, 2002  Group: 1614							
Filing Date O	February 13, 2002		Group: -161	4- 1621	4 70	JUN 1 8 2000	
JUN 1			TE(				
P	ě.	U.S. PATENT	DOCUMENTS			1600/2900	
Examiner & TR Initial*	ADVMA Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate	
FOREIGN PATENT DOCUMENTS							
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Of	Masui et al., Stereoselective Synthesis of 1,2-Amino Alcohols by Asymmetric Borane Reduction of α-Oxoketoxime Ethers, Tetrahedron Letters 39 (1998) 5195-5198						
(DL	Moroi, et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury in Mice, The Journal of Clinical Investigation, Vol. 101, No. 6, March 1998, 1225-1232						
OR.	Nakayama, et al., T <sup>-786</sup> →C Mutation in the 5' -Flanking Region of the Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm, Clinical Investigation and Reports, 2864-2870 (1999)						
Øg.	Sessa et al., Chronic Exercise in Dogs Increases Coronary Vascular Nitric Oxide Production and Endothelial Cell Nitric Oxide Synthase Gene Expression, Circulation Research, 74(2):349-353,1994						
OB	Trillat et al., (-)-5-Methyl-8-hydroxy-(di- <i>n</i> -propylamino)tetralin: A new 5-HT <sub>1A</sub> receptor antagonist, Eur. J. Med. Chem. 33 (1998) 437-444						
VDK.	Tschaen et al., Asymmetric Synthesis of MK-0499, J. Org. Chem. 60 (1995) 4324-4330						
ØJ.	Varenne et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Human Gene Therapy 11:1329-1339 (June 10, 2000)						
Windaus, Chem.Ber. 57 (1924) 1735-1737							
	10	0		4 7		·	
Examiner	Marger Kler	1	Date Considered	3/19/			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Form PTO 1449		Patent and	Trademark Offi	ce - U.S.	. Departn	nent of Commerce	